Detalhe da pesquisa
1.
Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.
J Antimicrob Chemother
; 77(9): 2522-2531, 2022 08 25.
Artigo
Inglês
| MEDLINE | ID: mdl-35781341
2.
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
J Antimicrob Chemother
; 77(4): 1166-1177, 2022 03 31.
Artigo
Inglês
| MEDLINE | ID: mdl-35022730
3.
Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
Crit Care
; 26(1): 373, 2022 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36457059
4.
Molecular Characterization of Baseline Enterobacterales and Pseudomonas aeruginosa Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial.
Antimicrob Agents Chemother
; 65(3)2021 02 17.
Artigo
Inglês
| MEDLINE | ID: mdl-33318005
5.
Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial.
Crit Care
; 25(1): 354, 2021 10 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34600585
6.
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
Crit Care
; 25(1): 290, 2021 08 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34380538
7.
Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP).
Antimicrob Agents Chemother
; 64(12)2020 11 17.
Artigo
Inglês
| MEDLINE | ID: mdl-32988827
8.
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
J Antimicrob Chemother
; 72(1): 268-272, 2017 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27707990
9.
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
BMC Infect Dis
; 17(1): 316, 2017 05 02.
Artigo
Inglês
| MEDLINE | ID: mdl-28464828
10.
Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.
J Antimicrob Chemother
; 71(7): 2014-21, 2016 07.
Artigo
Inglês
| MEDLINE | ID: mdl-26994090
11.
Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis.
Microbiol Spectr
; : e0180023, 2023 Sep 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37698430
12.
Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.
Pediatr Infect Dis J
; 42(4): 292-298, 2023 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36689671
13.
Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial.
Ann Intensive Care
; 13(1): 8, 2023 Feb 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36773112
14.
Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection.
Pediatr Infect Dis J
; 42(7): 557-563, 2023 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37000942
15.
Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
J Antimicrob Chemother
; 67(10): 2463-9, 2012 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-22773741
16.
Daptomycin therapy for osteomyelitis: a retrospective study.
BMC Infect Dis
; 12: 133, 2012 Jun 12.
Artigo
Inglês
| MEDLINE | ID: mdl-22691420
17.
A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections.
Int J Infect Dis
; 123: 157-165, 2022 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-35987467
18.
Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
Int J Antimicrob Agents
; 57(3): 106278, 2021 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-33434676
19.
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
Lancet Infect Dis
; 19(12): 1299-1311, 2019 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31563344
20.
Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.
Int J Antimicrob Agents
; 52(3): 324-330, 2018 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-29596902